1 Min Read
* Ignyta Inc - announced new preclinical data for RXDX-106
* Ignyta Inc - in study, researchers demonstrated immune-mediated, single-agent anti-tumor activity of RXDX-106 in multiple tumor models Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.